🌍·8h agodiscovery
Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.
Publisher
P
Pluang
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Pluang
- Region
- Global
- Scope
- discovery
- Published
- June 26, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Pluang
Scope: discovery
Related coverage
More related coverage
BioPharma Dive/4h ago
At BIO, tension over China biotech deal regulation looms
Investing.com/4h ago
UBS raises Incyte stock price target to $113 on biotech recovery
PharmTech.com/4h ago
Thermo Fisher's Kane Says AI Is Reshaping How CDMOs Add Value
TradingView/4h ago